Ni Xiao, Richmond Heather M, Liao Xingsheng M, Decker William K, Shiue Lisa H, Shpall Elizabeth J, Duvic Madeleine
Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Department of Dermatology, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
J Invest Dermatol. 2008 Nov;128(11):2631-2639. doi: 10.1038/jid.2008.125. Epub 2008 May 15.
Sézary syndrome (SzS), the leukemic variant of cutaneous T-cell lymphomas, is incurable. Dendritic cells (DCs) transfected with tumor mRNA can stimulate antitumor immunity in certain cancer patients. In this study, we determined whether mRNAs from Sézary cells could be used for loading DCs and stimulating antitumor immunity. Autologous DCs were generated from monocytes of the peripheral blood from 10 patients with SzS. Total RNA was extracted from Sézary cells and amplified by T7 in vitro transcription. The induction of antitumor IFN-gamma and granzyme B (GrB)-producing cytotoxic T lymphocytes (CTL) by RNA-transfected DCs was determined by ELISPOT assays. We found that IFN-gamma was required for IL-12p70 production by monocyte-derived DCs from SzS. The oncogenic transcription factor Twist and the tyrosine kinase receptor EphA4 were expressed in total RNA from Sézary cells and the paired amplified mRNAs. RNA-transfected DCs induced antitumor IFN-gamma-producing CTLs in 7 of 10 subjects and GrB-producing CTLs in 6 of 9 subjects. Both CD3+CD8+ T cells and CD4+CD25+ T cells were expanded without induction of regulatory T cells. These data support the concept of using tumor mRNA for a vaccine strategy that requires small amounts of tumor cells without need for specific antigens in patients with SzS.
蕈样肉芽肿综合征(SzS)是皮肤T细胞淋巴瘤的白血病变体,无法治愈。用肿瘤mRNA转染的树突状细胞(DC)可在某些癌症患者中刺激抗肿瘤免疫。在本研究中,我们确定来自蕈样肉芽肿细胞的mRNA是否可用于负载DC并刺激抗肿瘤免疫。从10例SzS患者的外周血单核细胞中生成自体DC。从蕈样肉芽肿细胞中提取总RNA,并通过T7体外转录进行扩增。通过ELISPOT分析确定RNA转染的DC诱导产生抗肿瘤干扰素-γ和颗粒酶B(GrB)的细胞毒性T淋巴细胞(CTL)的情况。我们发现,来自SzS的单核细胞衍生DC产生IL-12p70需要干扰素-γ。致癌转录因子Twist和酪氨酸激酶受体EphA4在蕈样肉芽肿细胞的总RNA和配对的扩增mRNA中表达。RNA转染的DC在10名受试者中的7名中诱导产生抗肿瘤干扰素-γ的CTL,在9名受试者中的6名中诱导产生GrB的CTL。CD3 + CD8 + T细胞和CD4 + CD25 + T细胞均扩增,且未诱导调节性T细胞。这些数据支持在SzS患者中使用肿瘤mRNA进行疫苗策略的概念,该策略需要少量肿瘤细胞且无需特定抗原。